Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individualizing phenobarbital dosing in neonates.

M E Gilman, J W Toback, P Gal

    Clinical Pharmacy
    |May 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Safety of a gastropexy device in infants and young children in percutaneous endoscopic gastrostomy tube placement.

    Scientific reports·2025
    Same author

    Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study.

    Frontiers in immunology·2022
    Same author

    Genistein does not inhibit TGF-beta1-induced conversion of human dermal fibroblasts to myofibroblasts.

    Physiological research·2021
    Same author

    Early Changes during Skin Repair Using Tissue-Engineered Dermal Template in a Full-Thickness Burn.

    Folia biologica·2021
    Same author

    Genistein Induces Bcl-2 Expression in Human Dermal Microvascular Endothelial Cells: a Short Report.

    Folia biologica·2021
    Same author

    Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development.

    Brain, behavior, and immunity·2020
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    A new method estimates phenobarbital elimination rate constants in neonates using two serum samples. This approach aids in personalized phenobarbital dosing, improving therapeutic drug monitoring for better patient outcomes.

    Area of Science:

    • Neonatal pharmacology
    • Clinical pharmacokinetics
    • Pediatric drug monitoring

    Background:

    • Phenobarbital is frequently used in neonates for various conditions.
    • Accurate dosing is crucial due to immature metabolic pathways in neonates.
    • Individualized dosing requires reliable estimation of drug elimination rates.

    Purpose of the Study:

    • To develop and validate a method for estimating phenobarbital elimination rate constants in neonates.
    • To assess the clinical utility of this method for individualizing phenobarbital therapy.
    • To compare predicted versus actual phenobarbital serum concentrations.

    Main Methods:

    • A two-sample method was developed to calculate elimination rate constants.
    • Phenobarbital serum concentrations were measured in 16 neonates.

    Related Experiment Videos

  • Elimination rate constants were used to adjust maintenance doses and predict future concentrations.

    • Main Results:

    • The method accurately estimated phenobarbital elimination rate constants.
    • Predicted serum concentrations on day 7 did not significantly differ from measured concentrations.
    • Phenobarbital half-life did not correlate with gestational or postnatal age.
    • Only one patient experienced phenobarbital toxicity.

    Conclusions:

    • The developed method is clinically useful for individualizing phenobarbital dosing in neonates.
    • This approach integrates therapeutic drug monitoring with maintenance dosing.
    • It allows for dosing adjustments based on individual metabolic capacity.